Physician profile
David R Marks
NPI 1841486149
$5,021.84
in general payments reported to CMS, 2019-2025
28 companies · $573 in 2025
The $573 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $421 · 2020: $686 · 2021: $205 · 2022: $854 · 2023: $1,265 · 2024: $1,018 · 2025: $573.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,856.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,856.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,402.04 | 2021-2025 | |
| Glaxosmithkline, LLC. | $768.66 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $542.01 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $472.06 | 2019-2025 | Breztri, Farxiga |
| Novartis Pharmaceuticals Corporation | $287.64 | 2019-2025 | |
| Lilly USA, LLC | $218.57 | 2019-2024 | Zepbound, Mounjaro, Jardiance |
| Novo Nordisk INC | $173.44 | 2019-2022 | |
| Amgen INC. | $137.48 | 2019-2024 | Repatha, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $133.25 | 2022-2024 | Xifaxan |
| E.R. Squibb & Sons, L.L.C. | $94.68 | 2022-2024 | Eliquis |
| Impel Pharmaceuticals INC. | $91.87 | 2023 | Trudhesa |
| Biohaven Pharmaceutical Holding Company LTD. | $78.86 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $74.67 | 2020 | |
| Exact Sciences Corporation | $71.33 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Allergan, INC. | $60.50 | 2019-2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $59.73 | 2019 | |
| Braeburn INC. | $51.58 | 2023-2025 | Brixadi |
| Alkermes, INC. | $48.04 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $44.31 | 2019-2020 | |
| Eisai INC. | $41.56 | 2020 | |
| Bausch Health US, LLC | $37.62 | 2019 | |
| Merck Sharp & Dohme LLC | $33.32 | 2022-2023 | Gardasil 9 |
| Janssen Pharmaceuticals, INC | $21.00 | 2023 | Xarelto |
| Sumitomo Pharma America, INC. | $20.14 | 2023 | Gemtesa |
| Orexo US, INC. | $15.00 | 2020 | |
| Astellas Pharma US INC | $14.75 | 2020 | |
| Intra-Sana Laboratories | $14.55 | 2025 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Almatica Pharma LLC | $13.18 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Marks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.